Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>S&amp;P DJI have proposed methodology changes to the S&amp;P/ASX family of indices to enhance representativeness and more quickly reflecting changing market conditions.</li>
<li>The main changes are lowering the minimum float threshold, shortening the market cap calculation period and the liquidity calculation period, and including buffers for additions and deletions.</li>
<li>We currently forecast 47 changes to the S&amp;P/ASX family of indices in September and the short market cap computation period could lead to more change over the next two months.</li>
</ul>


S&amp;P DJI have proposed methodology changes to the S&amp;P/ASX family of indices to enhance representativeness and more quickly reflecting changing market conditions.
The main changes are lowering the minimum float threshold, shortening the market cap calculation period and the liquidity calculation period, and including buffers for additions and deletions.
We currently forecast 47 changes to the S&amp;P/ASX family of indices in September and the short market cap computation period could lead to more change over the next two months.


S&P/ASX Indices: Proposed Methodology Changes & The BIG September Rebalance

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

Equity Bottom-Up

<ul><li>Auguring well for upcoming interim results, Regal Partners has provided a positive quarterly update showing a rebound for funds under management and performance fees.</li><li> -Regal Partners&rsquo; positive June quarter update -FUM and performance fees rebound -Management raises normalised profit guidance -Share price undervalued, suggests Bell Potter</li></ul>

Auguring well for upcoming interim results, Regal Partners has provided a positive quarterly update showing a rebound for funds under management and performance fees. -Regal Partners&rsquo; positive June quarter update -FUM and performance fees rebound -Management raises normalised profit guidance -Share price undervalued, suggests Bell Potter

Regal Partners Recovers Performance Fee Mojo

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jun 27th (reported today). The aggregated short interest was USD25.9bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in National Australia Bank, Cochlear, Northern Star Resources, Brambles, Westpac.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jun 27th (reported today). The aggregated short interest was USD25.9bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in National Australia Bank, Cochlear, Northern Star Resources, Brambles, Westpac.


ASX Short Interest Weekly (Jun 27th): National Australia Bank, Cochlear, Northern Star Resources

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jun 20th (reported today). The aggregated short interest was USD25.9bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia, Evolution Mining, BHP, National Australia Bank, Westpac.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jun 20th (reported today). The aggregated short interest was USD25.9bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia, Evolution Mining, BHP, National Australia Bank, Westpac.


ASX Short Interest Weekly (Jun 20th): Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia

Global Healthcare Analyst

Tina Banerjee

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.</li>
<li>The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&amp;D tax incentive. This provides cash runway through 2H26.</li>
<li>Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization. </li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.
The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&amp;D tax incentive. This provides cash runway through 2H26.
Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization. 


Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

Australia

Opthea Limited is a biologics drug developer for ophthalmic diseases. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Opthea Ltd (OPT AU)

S&P/ASX Indices: Proposed Methodology Changes & The BIG September Rebalance

The market consultation ends in 2 weeks, and the conclusions should be announced soon after that. A lot of the stocks have moved significantly over...

Brian Freitas

Regal Partners Recovers Performance Fee Mojo

Auguring well for upcoming interim results, Regal Partners has provided a positive quarterly update showing a rebound for funds under management...

FNArena

ASX Short Interest Weekly (Jun 27th): National Australia Bank, Cochlear, Northern Star Resources

We analyzed ASX short interest report for the past week and highlight short interest changes in National Australia Bank, Cochlear, Northern Star...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jun 20th): Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia

We analyzed ASX short interest report for the past week and highlight short interest changes in Sigma Pharmaceuticals (SIG AU), Brambles (BXB AU),...

Ke Yan, CFA, FRM

Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

S&P/ASX Indices: Proposed Methodology Changes & The BIG September Rebalance

The market consultation ends in 2 weeks, and the conclusions should be announced soon after that. A lot of the stocks have moved significantly over...

Brian Freitas

Regal Partners Recovers Performance Fee Mojo

Auguring well for upcoming interim results, Regal Partners has provided a positive quarterly update showing a rebound for funds under management...

FNArena

ASX Short Interest Weekly (Jun 27th): National Australia Bank, Cochlear, Northern Star Resources

We analyzed ASX short interest report for the past week and highlight short interest changes in National Australia Bank, Cochlear, Northern Star...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jun 20th): Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia

We analyzed ASX short interest report for the past week and highlight short interest changes in Sigma Pharmaceuticals (SIG AU), Brambles (BXB AU),...

Ke Yan, CFA, FRM

Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

​Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Tina Banerjee

Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...